Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 1
2002 3
2004 5
2005 5
2006 6
2007 4
2008 1
2009 3
2010 10
2011 12
2012 15
2013 7
2014 7
2015 15
2016 12
2017 11
2018 8
2019 20
2020 15
2021 17
2022 8
2023 14
2024 16
2025 11
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Results by year

Filters applied: . Clear all
Page 1
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Melero I, et al. Among authors: joerger m. Nature. 2025 Jan;637(8048):1218-1227. doi: 10.1038/s41586-024-08305-z. Epub 2024 Dec 11. Nature. 2025. PMID: 39663448 Free PMC article. Clinical Trial.
Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial.
Güller U, Hayoz S, Horber D, Jochum W, De Dosso S, Koeberle D, Schacher S, Inauen R, Stahl M, Delaunoit T, Ettrich T, Bodoky G, Michel P, Koessler T, Rothgiesser K, Calmonte S, Joerger M. Güller U, et al. Among authors: joerger m. Clin Cancer Res. 2025 Aug 1;31(15):3142-3149. doi: 10.1158/1078-0432.CCR-24-4048. Clin Cancer Res. 2025. PMID: 40067142 Free PMC article. Clinical Trial.
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Nuñez NG, et al. Among authors: joerger m. Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. Med. 2023. PMID: 36693381 Free article.
Non-pharmaceutical interventions to optimize cancer immunotherapy.
Boesch M, Baty F, Rassouli F, Kowatsch T, Joerger M, Früh M, Brutsche MH. Boesch M, et al. Among authors: joerger m. Oncoimmunology. 2023 Sep 28;12(1):2255459. doi: 10.1080/2162402X.2023.2255459. eCollection 2023. Oncoimmunology. 2023. PMID: 37791231 Free PMC article. Review.
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Melero I, et al. Among authors: joerger m. Nature. 2025 Mar;639(8054):E18. doi: 10.1038/s41586-025-08827-0. Nature. 2025. PMID: 40000750 Free PMC article. No abstract available.
Gemcitabine-associated hemolytic-uremic syndrome.
Walter RB, Joerger M, Pestalozzi BC. Walter RB, et al. Among authors: joerger m. Am J Kidney Dis. 2002 Oct;40(4):E16. doi: 10.1053/ajkd.2002.35758. Am J Kidney Dis. 2002. PMID: 12324937 Review.
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum AK, Purde MT, Abdou MT, Sinnberg T, Hofmeister K, Pop OT, Hasan Ali O, Bauer J, Cheng HW, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer BS, Driessen C, Schürch CM, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy AN, Schneider T, Brutsche MH, Sette A, Lenz TL, Walz J, Rammensee HG, Früh M, Jäger E, Becher B, Tufman A, Nuñez N, Joerger M, Flatz L. Wyss N, et al. Among authors: joerger m. Am J Respir Crit Care Med. 2024 Oct 1;210(7):919-930. doi: 10.1164/rccm.202311-2136OC. Am J Respir Crit Care Med. 2024. PMID: 38626354
Metabolism of the taxanes including nab-paclitaxel.
Joerger M. Joerger M. Expert Opin Drug Metab Toxicol. 2015 May;11(5):691-702. doi: 10.1517/17425255.2015.983074. Epub 2014 Nov 14. Expert Opin Drug Metab Toxicol. 2015. PMID: 25394848 Review.
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.
Yap TA, Tan DSP, Stathis A, Shapiro GI, Iwasa S, Joerger M, Zhang J, Plummer R, Sawyer MB, Tan DSW, Castonguay V, Gabrail NY, Matsubara N, Wilkinson G, Ludwig M, Schlicker A, Zhou Y, Merz C, Däbritz JHM, Jeffers M, Hreiki J, de Bono JS. Yap TA, et al. Among authors: joerger m. Cancer Discov. 2025 Oct 6;15(10):2019-2035. doi: 10.1158/2159-8290.CD-24-1500. Cancer Discov. 2025. PMID: 40516108 Clinical Trial.
191 results